Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 5 August 2021, 10:45 HKT/SGT
Share:
    

Source: Eisai
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards

TOKYO, Aug 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo).

The Corporate Communications Awards were established in 1984 with the aim of advancing the field by recognizing companies and individuals that practice excellent corporate communications. There are three awards: the Award for Excellence in Corporate Communications, Outstanding Leadership Awards in Corporate Communications, and the Outstanding Merit Awards.

The Award for Excellence in Corporate Communications received by Eisai is given to the company that contribute to society by identifying what is expected and required of them by society, reflecting this in their management, and disseminating and communicating accurate information about their corporate activities to their stakeholders through public relations initiatives.

The award was presented to Eisai in recognition of its efforts to promote understanding of dementia, which has become a social issue, by providing not only information on the status of new drug development, but also on the latest findings on the pathological condition of the disease and the social burden of nursing care, as well as efforts to promote understanding among stakeholders through study sessions for scientific and medical journalists and providing easy-to-understand explanations of difficult science, thereby making a significant contribution to increase the benefits of patients and their families in line with its corporate philosophy of human health care (hhc).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In the new medium-term business plan "EWAY Future & Beyond" started in FY2021, based on the hhc philosophy, Eisai aims to remove the anxiety of "The People", including not only patients but also society at large, by delivering not only pharmaceutical products but also solutions to The People. In order to realize the hhc philosophy, we will make further contributions to increase the benefits to "The People" by enhancing corporate value through public relations activities.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: